{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:18:47Z","timestamp":1790011127162,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["Grant NO. 82170077"],"award-info":[{"award-number":["Grant NO. 82170077"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Project supported by Medical Science and Technology Development Foundation, Nanjing Department of Health","award":["YKK20051"],"award-info":[{"award-number":["YKK20051"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-025-03635-8","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T14:05:56Z","timestamp":1744293956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of anlotinib monotherapy or combination therapy in the treatment of patients with advanced non-small cell lung cancer: a retrospective real-world study conducted in East China"],"prefix":"10.1186","volume":"25","author":[{"given":"Jia","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"7","key":"3635_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen H-D, Yu Y-W, Li N, Chen W-Q. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783\u201391.","journal-title":"Chin Med J"},{"issue":"6","key":"3635_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. Cancer J Clin. 2019;69(6):438\u201351.","journal-title":"Cancer J Clin"},{"issue":"8","key":"3635_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.11058","volume":"322","author":"KC Arbour","year":"2019","unstructured":"Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non\u2013small cell lung cancer: a review. JAMA. 2019;322(8):764\u201374.","journal-title":"JAMA"},{"issue":"1","key":"3635_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev-pharmtox-010716-104523","volume":"58","author":"DC Wang","year":"2018","unstructured":"Wang DC, Wang W, Zhu B, Wang X. Lung cancer heterogeneity and new strategies for drug therapy. Annu Rev Pharmacol Toxicol. 2018;58(1):531\u201346.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"101","key":"3635_CR5","doi-asserted-by":"publisher","first-page":"37589","DOI":"10.18632\/oncotarget.26428","volume":"9","author":"X Ai","year":"2018","unstructured":"Ai X, Guo X, Wang J, Stancu AL, Joslin PM, Zhang D, Zhu S. Targeted therapies for advanced non-small cell lung cancer. Oncotarget. 2018;9(101):37589.","journal-title":"Oncotarget"},{"key":"3635_CR6","doi-asserted-by":"publisher","first-page":"175883401774501","DOI":"10.1177\/1758834017745012","volume":"10","author":"I Moya-Horno","year":"2018","unstructured":"Moya-Horno I, Viteri S, Karachaliou N, Rosell R. Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Therapeutic Adv Med Oncol. 2018;10:1758834017745012.","journal-title":"Therapeutic Adv Med Oncol"},{"key":"3635_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lungcan.2021.08.006","volume":"160","author":"N Zhou","year":"2021","unstructured":"Zhou N, Jiang M, Li T, Zhu J, Liu K, Hou H, Zhang X. Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: an open-label, dose escalation and expansion study. Lung Cancer. 2021;160:111\u20137.","journal-title":"Lung Cancer"},{"issue":"1","key":"3635_CR8","first-page":"687","volume":"16","author":"T Li","year":"2018","unstructured":"Li T, Kang G, Wang T, Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett. 2018;16(1):687\u2013702.","journal-title":"Oncol Lett"},{"key":"3635_CR9","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77:1745\u201370.","journal-title":"Cell Mol Life Sci"},{"key":"3635_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","volume":"654","author":"B Lin","year":"2018","unstructured":"Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1. Gene. 2018;654:77\u201386.","journal-title":"Gene"},{"issue":"4","key":"3635_CR11","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"C Xie","year":"2018","unstructured":"Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109(4):1207\u201319.","journal-title":"Cancer Sci"},{"issue":"11","key":"3635_CR12","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non\u2013small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569\u201375.","journal-title":"JAMA Oncol"},{"issue":"2","key":"3635_CR13","doi-asserted-by":"publisher","first-page":"e004025","DOI":"10.1136\/jitc-2021-004025","volume":"10","author":"T Seto","year":"2022","unstructured":"Seto T, Nosaki K, Shimokawa M, Toyozawa R, Sugawara S, Hayashi H, Murakami H, Kato T, Niho S, Saka H. Phase II study of Atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@ be Study). J Immunother Cancer. 2022;10(2):e004025.","journal-title":"J Immunother Cancer"},{"issue":"31","key":"3635_CR14","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.2217\/fon-2021-0649","volume":"17","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang C, Yang S, Chen Q, Wang C, Guo Q. Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study. Future Oncol. 2021;17(31):4091\u20139.","journal-title":"Future Oncol"},{"issue":"2","key":"3635_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3635_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas dermo-sifiliograficas. 2021;112(1):90\u20132.","journal-title":"Actas dermo-sifiliograficas"},{"issue":"3","key":"3635_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"1","key":"3635_CR18","first-page":"1475871","volume":"2022","author":"L Li","year":"2022","unstructured":"Li L, Zhang H, Xie Y, Su N, Su S, Zhang X, Cen W. [Retracted] the efficacy and safety of anlotinib alone and in combination with other drugs in advanced lung cancer: A retrospective cohort study. Comput Math Methods Med. 2022;2022(1):1475871.","journal-title":"Comput Math Methods Med"},{"issue":"1","key":"3635_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12890-022-01981-5","volume":"22","author":"W Wang","year":"2022","unstructured":"Wang W, Shao L, Xu Y, Song Z, Lou G, Zhang Y, Chen M. Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study. BMC Pulm Med. 2022;22(1):179.","journal-title":"BMC Pulm Med"},{"issue":"7","key":"3635_CR20","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.annonc.2021.03.199","volume":"32","author":"K Rzeniewicz","year":"2021","unstructured":"Rzeniewicz K, Larkin J, Menzies A, Turajlic S. Immunotherapy use outside clinical trial populations: never say never? Ann Oncol. 2021;32(7):866\u201380.","journal-title":"Ann Oncol"},{"key":"3635_CR21","doi-asserted-by":"crossref","unstructured":"Zhang P, Ma M, Nie J, Dai L, Hu W, Zhang J, Wu D, Chen X, Ma X, Tian G. Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged\u2009\u2265\u200975 years) with advanced non-small cell lung cancer. Heliyon 2024, 10(4).","DOI":"10.1016\/j.heliyon.2024.e26026"},{"key":"3635_CR22","doi-asserted-by":"crossref","unstructured":"Shi J, Han B, Li K, Wang Q, Zhang L, Zhe-Hai W, Cheng Y, He J, Shi Y, Chen W. The efficacy of anlotinib in squamous cell carcinoma (SCC) patients with or without hypertension in ALTER0303: anlotinib as a third-line therapy in patients with advanced non-small cell lung cancer (NSCLC). In.: American Society of Clinical Oncology; 2019.","DOI":"10.1200\/JCO.2019.37.15_suppl.e20503"},{"issue":"5","key":"3635_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng Y, Gao Y, Li K. Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11(5):309.","journal-title":"Cell Death Dis"},{"key":"3635_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint Blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:1\u201312.","journal-title":"Mol Cancer"},{"key":"3635_CR25","doi-asserted-by":"publisher","first-page":"1265865","DOI":"10.3389\/fimmu.2023.1265865","volume":"14","author":"D He","year":"2023","unstructured":"He D, Wang L, Xu J, Zhao J, Bai H, Wang J. Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer. Front Immunol. 2023;14:1265865.","journal-title":"Front Immunol"},{"issue":"4","key":"3635_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","volume":"16","author":"T Chu","year":"2021","unstructured":"Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, Qian J, Zhang Y, Chang Q, Zhang X. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol. 2021;16(4):643\u201352.","journal-title":"J Thorac Oncol"},{"key":"3635_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:1\u201311.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"3635_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","volume":"11","author":"F Song","year":"2020","unstructured":"Song F, Hu B, Cheng J-W, Sun Y-F, Zhou K-Q, Wang P-X, Guo W, Zhou J, Fan J, Chen Z. Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020;11(7):573.","journal-title":"Cell Death Dis"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03635-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T14:06:00Z","timestamp":1744293960000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03635-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3635"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03635-8","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). All the patients have been informed and the Written informed consent was obtained from all individual participants included in the study prior to enrollment. The study was approved by the Medical Ethics Committee of Nanjing Drum Tower Hospital. (Ethics No. 2020-137-13).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript in accordance with ICMJE criteria. This article is original, has not already been published in a journal, and is not currently under consideration by another journal. We agree to the terms of the BioMed Central Copyright and License Agreement.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All authors declare no conflicts of interest associated with this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}